Fulltext
Fulltext
General population
(no diabetes or CKD) Diabetes or CKD present
Age ≥60 years Age <60 years All ages All ages
Diabetes present CKD present with
No CKD or without diabetes
Blood pressure goal Blood pressure goal Blood pressure goal Blood pressure goal
SBP <150 mm Hg SBP <140 mm Hg SBP <140 mm Hg SBP <140 mm Hg
DBP <90 mm Hg DBP <90 mm Hg DBP <90 mm Hg DBP <90 mm Hg
Initiate thiazide-type diuretic Initiate thiazide-type diuretic Initiate ACEI or ARB, alone
or ACEI or ARB or CCB, alone or CCB, alone or in combination with other
or in combination.a or in combination. drug class.a
Select a drug treatment titration strategy
Gambar 1. Algoritme Penanganan Hipertensi berdasarkan JNC 8
A. Maximize first medication before adding second or
B. Add second medication before reaching maximum dose of first medication or
Penanganan
C. Start hipertensi
with 2 medication memiliki beberapa
classes separately or as fixed-dosepedoman
combination. yang terkadang
menimbulkan kerancuan bagi pengguna pedoman tersebut. JNC 8 memiliki
Yes
At goal blood pressure?
kelebihan karena tim penyusun terdiri dari multi disiplin. Bagaimanapun
No
berbagai pedoman penanganan
Reinforce hipertensi
medication and lifestyle adherence. tersebut dapat memberikan sudut
For strategies A and B, add and titrate thiazide-type diuretic or ACEI or ARB or CCB (use
pandang yang berbeda. Tetapi
medication class bagaimana
not previously posisi
selected and avoid ACEI
combined pada
use of berbagai
ACEI and ARB). pedoman
For strategy C, titrate doses of initial medications to maximum.
lainnya?
Sejak tahun 2011 terdapat Atbeberapa pedoman
goal blood pressure?
Yes yang dapat membantu
berdasarkan NICE.
Table 6. Guideline Comparisons of Goal BP and Initial Drug Therapy for Adults With Hypertension
Goal BP,
Guideline Population mm Hg Initial Drug Treatment Options
2014 Hypertension General ≥60 y <150/90
guideline Nonblack: thiazide-type diuretic, ACEI,
General <60 y <140/90 ARB, or CCB; black: thiazide-type diuretic
or CCB
Diabetes <140/90
CKD <140/90 ACEI or ARB
37
ESH/ESC 2013 General nonelderly <140/90
General elderly <80 y <150/90 Diuretic, β-blocker, CCB, ACEI, or ARB
General ≥80 y <150/90
Diabetes <140/85 ACEI or ARB
CKD no proteinuria <140/90 Abbreviatio
ACEI or ARB
CKD + proteinuria <130/90 Diabetes As
CHEP 201338 General <80 y <140/90 angiotensin
Thiazide, β-blocker (age <60y), ACEI inhibitor; AR
General ≥80 y <150/90 (nonblack), or ARB
blocker; CC
Diabetes <130/80 ACEI or ARB with additional CVD risk blocker; CH
ACEI, ARB, thiazide, or DHPCCB without Hypertensio
additional CVD risk
CKD, chron
CKD <140/90 ACEI or ARB cardiovascu
ADA 201339 Diabetes <140/80 ACEI or ARB dihydropyri
KDIGO 2012 40
CKD no proteinuria ≤140/90 blocker; ESC
ACEI or ARB Cardiology;
CKD + proteinuria ≤130/80 Hypertensio
NICE 201141 General <80 y <140/90 <55 y: ACEI or ARB Society for H
General ≥80 y <150/90 ≥55 y or black: CCB JNC, Joint N
42 KDIGO, Kidn
ISHIB 2010 Black, lower risk <135/85 Global Outc
Target organ damage Diuretic or CCB
<130/80penanganan Hipertensi
Tabel 1. Perbandingan berbagai paduan Institute for
or CVD risk Excellence.
line was not endorsed by any federal agency or professional society JNC 8. The charge to the committee was as fo
prior to publication and thus is a departure from previous JNC reports. review and synthesize the latest available sc
The panel anticipates that an objective assessment of this report fol- date existing clinical recommendations, and pr
publication will allow open dialogue among endorsing enti-
lowing primary care clinicians on the best approache
ties and encourage continued attention to rigorous methods in guide- trol hypertension in order to minimize patien
line development, thus raising the standard for future guidelines. cular and other complications.” The commit
identify and prioritize the most important q
dence review. In June 2013, NHLBI announc
continue developing clinical guidelines inclu
Discussion
instead partnering with selected organization
The recommendations based on RCT evidence in this guideline dif- the guidelines.43,44 Importantly, participati
fer from recommendations in other currently used guidelines sup- quired that these organizations be involved